#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14646	16S	1529	1529	100.0	16S.l15.c17.ctg.2	2275	769.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1450	1450	C	913	C,T	911,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14646	16S	1529	1529	100.0	16S.l15.c17.ctg.2	2275	769.2	0	HET	.	.	.	A69G	.	69	69	A	335	335	A	909	A,G	710,198	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24754	23S	2890	2890	99.9	23S.l6.c30.ctg.1	4170	739.3	0	.	n	.	0	T695C	SNP	695	695	T	1399	1399	C	877	C,T,G	875,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24754	23S	2890	2890	99.9	23S.l6.c30.ctg.1	4170	739.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	2041	2041	A	985	A,C	983,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24754	23S	2890	2890	99.9	23S.l6.c30.ctg.1	4170	739.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2675	2675	C	855	C,T	853,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24754	23S	2890	2890	99.9	23S.l6.c30.ctg.1	4170	739.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2749	2749	A	774	A	772	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24754	23S	2890	2890	99.9	23S.l6.c30.ctg.1	4170	739.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3301	3301	C	885	C,T,G	883,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2136	folP	855	855	100.0	folP.l15.c17.ctg.1	2114	126.0	1	SNP	p	R229S	1	.	.	685	687	AGC	1293	1295	AGC	217;218;219	A;G;C,T	217;218;218,1	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5192	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3780	171.1	1	SNP	p	S91F	1	.	.	271	273	TTC	750	752	TTC	196;195;196	T,G;T;C	195,1;195;196	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5192	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3780	171.1	1	SNP	p	G95N	0	.	.	283	285	GGC	762	764	GGC	203;203;203	G,C;G,C;C	202,1;202,1;203	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5192	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3780	171.1	1	SNP	p	D95G	1	.	.	283	285	GGC	762	764	GGC	203;203;203	G,C;G,C;C	202,1;202,1;203	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	1874	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1918	121.5	1	SNP	p	G45D	0	.	.	133	135	GGC	797	799	GGC	215;215;214	G,T;G;C	214,1;215;214	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1012	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1493	84.4	0	.	n	.	0	A197.	DEL	197	197	A	898	898	A	218	A	218	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4602	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3589	159.8	1	SNP	p	D86N	0	.	.	256	258	GAC	922	924	GAC	231;232;232	G;A,C;C	231;231,1;232	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4602	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3589	159.8	1	SNP	p	S87R	1	.	.	259	261	CGT	925	927	CGT	233;237;235	C,A,G;G,C;T,G,A	229,3,1;236,1;233,1,1	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4602	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3589	159.8	1	SNP	p	R87I	0	.	.	259	261	CGT	925	927	CGT	233;237;235	C,A,G;G,C;T,G,A	229,3,1;236,1;233,1,1	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4602	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3589	159.8	1	SNP	p	R87W	0	.	.	259	261	CGT	925	927	CGT	233;237;235	C,A,G;G,C;T,G,A	229,3,1;236,1;233,1,1	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4602	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3589	159.8	1	SNP	p	S88P	0	.	.	262	264	TCC	928	930	TCC	237;239;239	T,G;C;CG,C	236,1;238;228,1	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4196	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3286	159.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1811	1813	GGC	239;239;236	G,C;G;C	238,1;239;236	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	3964	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2858	172.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1551	1553	GCA	215;215;215	G;C;A,C	215;214;214,1	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3964	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2858	172.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1554	1556	ATC	213;211;211	A,T,C;T,G,C;C	210,1,2;209,1,1;211	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3964	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2858	172.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1566	1568	GTG	207;206;206	G,T,A;T,A;G	205,1,1;205,1;206	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3964	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2858	172.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1566	1568	GTG	207;206;206	G,T,A;T,A;G	205,1,1;205,1;206	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3964	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2858	172.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2070	2072	ACC	226;226;226	A,C;C;C	224,1;226;226	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3964	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2858	172.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2124	2126	GCG	247;244;243	G;C,G;G,A,C	247;243,1;241,1,1	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3964	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2858	172.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2124	2126	GCG	247;244;243	G;C,G;G,A,C	247;243,1;241,1,1	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3964	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2858	172.4	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2247	2249	AGC	202;198;196	A;G;C,G	202;198;195,1	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3964	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2858	172.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2256	2258	GGC	202;206;207	G;G,A;C	202;204,1;207	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3964	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2858	172.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2274	2276	CCG	207;208;208	C,G;C,T,A;G,A,T	206,1;206,1,1;206,1,1	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5460	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3528	192.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1877	1879	CCG	241;243;243	C;C,A;G	241;242,1;243	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2278	porA	1146	1146	99.91	porA.l15.c4.ctg.1	2389	118.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	845	845	C	173	C	173	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	248	porB1a	984	100	94.0	porB1a.l6.c17.ctg.2	169	45.8	0	.	p	.	0	M18T	NONSYN	52	54	ATG	120	122	ACG	53;50;49	A;C;G	53;50;49	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	248	porB1a	984	100	94.0	porB1a.l6.c17.ctg.2	169	45.8	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	162	164	CAA	14;13;10	C;A;A	14;13;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	248	porB1a	984	222	90.54	porB1a.l6.c17.ctg.3	270	25.0	0	.	p	.	0	V258L	NONSYN	772	774	GTA	13	15	TTA	27;29;32	T;T;A	27;29;32	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	248	porB1a	984	222	90.54	porB1a.l6.c17.ctg.3	270	25.0	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	58	60	CAT	52;52;52	C;A;T	52;52;52	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	248	porB1a	984	222	90.54	porB1a.l6.c17.ctg.3	270	25.0	0	.	p	.	0	D274S	NONSYN	820	822	GAT	61	63	AGT	52;52;52	A;G;T	52;52;52	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	248	porB1a	984	222	90.54	porB1a.l6.c17.ctg.3	270	25.0	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	70	72	TAC	52;52;52	T;A;C	52;52;52	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	248	porB1a	984	222	90.54	porB1a.l6.c17.ctg.3	270	25.0	0	.	p	.	0	R307A	NONSYN	919	921	AGA	160	162	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	248	porB1a	984	222	90.54	porB1a.l6.c17.ctg.3	270	25.0	0	.	p	.	0	T311A	NONSYN	931	933	ACA	172	174	GCA	1;1;2	G;C;A	1;1;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	248	porB1a	984	222	90.54	porB1a.l6.c17.ctg.3	270	25.0	0	.	p	.	0	E312D	NONSYN	934	936	GAA	175	177	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	248	porB1a	984	222	90.54	porB1a.l6.c17.ctg.3	270	25.0	0	.	p	.	0	F314I	NONSYN	940	942	TTC	181	183	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	248	porB1a	984	222	90.54	porB1a.l6.c17.ctg.3	270	25.0	0	.	p	.	0	A316S	NONSYN	946	948	GCG	187	189	TCG	2;2;2	T;C;G	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	248	porB1a	984	222	90.54	porB1a.l6.c17.ctg.3	270	25.0	0	.	p	.	0	V318A	NONSYN	952	954	GTC	193	195	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	248	porB1a	984	222	90.54	porB1a.l6.c17.ctg.3	270	25.0	0	.	p	.	0	G319S	NONSYN	955	957	GGC	196	198	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	248	porB1a	984	222	90.54	porB1a.l6.c17.ctg.3	270	25.0	0	.	p	.	0	G320A	NONSYN	958	960	GGT	199	201	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	248	porB1a	984	222	90.54	porB1a.l6.c17.ctg.3	270	25.0	0	.	p	.	0	G322V	NONSYN	964	966	GGT	205	207	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2902	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	2047	176.1	0	.	p	.	0	N38E	NONSYN	112	114	AAT	753	755	GAA	268;269;270	G,C;A,G;A	266,1;267,1;269	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2902	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	2047	176.1	0	.	p	.	0	K120N	NONSYN	358	360	AAG	999	1001	AAC	235;234;236	A,C;A;C	234,1;234;236	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2902	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	2047	176.1	0	.	p	.	0	N134D	NONSYN	400	402	AAT	1041	1043	GAT	255;255;257	G;A,C;T,A	255;254,1;256,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2902	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	2047	176.1	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1164	1166	TCA	281;279;277	T,G,A;C,A;A	279,1,1;278,1;277	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2902	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	2047	176.1	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1293	1295	GTC	240;236;233	G;T,G;C,T	240;235,1;232,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2902	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	2047	176.1	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1305	1307	TCT	232;233;235	T,G;C;T	231,1;233;235	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2902	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	2047	176.1	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1623	1625	GCA	213;215;218	G;C;A	213;215;218	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2902	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	2047	176.1	1	SNP	p	D121N	0	.	.	361	363	GAC	1002	1004	GAC	236;238;241	G;A;C	236;238;241	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2902	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	2047	176.1	1	SNP	p	A121D	1	.	.	361	363	GAC	1002	1004	GAC	236;238;241	G;A;C	236;238;241	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9610	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5311	225.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1520	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1415	133.4	1	SNP	p	V57M	1	.	.	169	171	ATG	715	717	ATG	273;274;273	A,G;T;G	272,1;274;273	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
